Neuralgia, PostherpeticPhase 2NCT00619476
A Study In Patients With Neuropathic Pain From Post-Herpetic Neuralgia (PHN)
A Phase 2 study testing GEn 1200mg/day, GEn 2400mg/day and GEn 3600mg/day in people with Neuralgia, Postherpetic, run by XenoPort, Inc. at 83 sites in 2 countries.
Trial summary
The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN). Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Neuralgia, Postherpetic
- What is being tested?
- GEn 1200mg/day, GEn 2400mg/day and GEn 3600mg/day
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 376 participants
- Where
- 83 sitesin 2 countries
- Study dates
- Feb 2008to Jul 2009
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 18 years or older
- Female subjects are eligible if of non-childbearing potential or not lactating, has a negative pregnancy, and agrees to use one a specified highly effective method for avoiding pregnancy
- Documented medical diagnosis of PHN of with pain present for at least three months from the healing of a herpes zoster rash
- Baseline 24-hour average pain intensity score ≥ 4.0 based on an 11-point PI-NRS
- Provides written informed consent in accordance with all applicable regulatory requirements
Who cannot join
- Other chronic pain conditions not associated with PHN. However, the subject will not be excluded if:
- The pain is located at a different region of the body; and
- The pain intensity is not greater than the pain intensity of the PHN; and
- The subject can assess PHN pain independently of other pain
- Is unable to discontinue prohibited medications or non-drug therapies or procedures throughout the duration of the study
- Hepatic impairment defined as ALT or AST > 2x upper limit of normal (ULN), or alkaline phosphatase or bilirubin > 1.5x ULN
Show all 25Show fewer
- Chronic hepatitis B or C
- Impaired renal function defined as creatinine clearance <60 mL/min or requiring hemodialysis
- Corrected QT (QTc) interval ≥ 450 msec or QTc interval ≥480 msec for patients with Bundle Branch Block
- Uncontrolled hypertension at screen (sitting systolic >160 mmHg and/or sitting diastolic >90 mmHg)
- Current diagnosis of active epilepsy or any active seizure disorder requiring chronic therapy with antiepileptic drugs
- Medical condition or disorder that would interfere with the action, absorption, distribution, metabolism, or excretion of GEn, or, in the investigator's judgment
- Is considered to be clinically significant and may pose a safety concern, or,
- Could interfere with the accurate assessment of safety or efficacy, or,
- Could potentially affect a subject's safety or study outcome
- Meets criteria defined by the DSM-IV-TR for a major depressive episode or for active significant psychiatric disorders within last year
- Depression in remission, with or without antidepressant treatment, may participate, unless stable antidepressant regimen is a prohibited medication
- Antidepressant medication may not be changed or discontinued to meet entry criteria and must be stable for at least three months prior to enrollment
- History of clinically significant drug or alcohol abuse (DSM-IV-TR) or is unable to refrain from substance abuse throughout the study. Benzodiazepines or atypical benzodiazepines as hypnotic sleep agents permitted.
- Currently participating in another clinical study in which the subject is, or will be exposed to an investigational or non-investigational drug or device
- Has participated in a clinical study and was exposed to investigational or non-investigational drug or device:
- Within preceding month for studies unrelated to PHN, or
- Within preceding six months for studies related to PHN
- Treated previously with GEn
- History of allergic or medically significant adverse reaction to investigational products (including gabapentin) or their excipients, acetaminophen or related compounds
Trial locations and contacts
83 sites in 2 countries.
83 sites in 2 countries
United States72 sites
GSK Investigational Site
Albuquerque, New Mexico, 87108
GSK Investigational Site
Altoona, Pennsylvania, 16602
GSK Investigational Site
Amherst, New York, 14226
GSK Investigational Site
Arcadia, California, 91007
GSK Investigational Site
Bingham Farms, Michigan, 48025
GSK Investigational Site
Birmingham, Alabama, 35205
GSK Investigational Site
Boston, Massachusetts, 02215
GSK Investigational Site
Boulder, Colorado, 80304
GSK Investigational Site
Bradenton, Florida, 34203
GSK Investigational Site
Bradenton, Florida, 34206
GSK Investigational Site
Brooklyn, New York, 11235
GSK Investigational Site
Chandler, Arizona, 85225
GSK Investigational Site
Charlotte, North Carolina, 28204
GSK Investigational Site
Chicago, Illinois, 60611
GSK Investigational Site
Cincinnati, Ohio, 45246
GSK Investigational Site
Danville, Indiana, 46122
GSK Investigational Site
Daytona Beach, Florida, 32117
GSK Investigational Site
Decatur, Georgia, 30033
GSK Investigational Site
Elkhart, Indiana, 46514
GSK Investigational Site
Eugene, Oregon, 97401
GSK Investigational Site
Gilbert, Arizona, 85234
GSK Investigational Site
Greensboro, North Carolina, 27408
GSK Investigational Site
Hallandale, Florida, 33009
GSK Investigational Site
Hickory, North Carolina, 28601
GSK Investigational Site
High Point, North Carolina, 27262
GSK Investigational Site
Hollywood, Florida, 33021
GSK Investigational Site
Huntington Park, California, 90255
GSK Investigational Site
Kansas City, Missouri, 64111
GSK Investigational Site
Lebanon, New Hampshire, 03766
GSK Investigational Site
Libertyville, Illinois, 60048
GSK Investigational Site
Litchfield Park, Arizona, 85340
GSK Investigational Site
Little Rock, Arkansas, 72205
GSK Investigational Site
Marietta, Georgia, 30066
GSK Investigational Site
Medford, Oregon, 97501
GSK Investigational Site
Milwaukee, Wisconsin, 53226
GSK Investigational Site
Naranja, Florida, 33032
GSK Investigational Site
New Port Beach, California, 92660
GSK Investigational Site
New Port Richey, Florida, 34652
GSK Investigational Site
New York, New York, 10004
GSK Investigational Site
New York, New York, 10128
GSK Investigational Site
Norman, Oklahoma, 73071
GSK Investigational Site
Northport, Alabama, 35476
GSK Investigational Site
Northridge, California, 91325
GSK Investigational Site
Ocala, Florida, 34471
GSK Investigational Site
Oklahoma City, Oklahoma, 73112
GSK Investigational Site
Olive Branch, Mississippi, 38654
GSK Investigational Site
Oxnard, California, 93030
GSK Investigational Site
Redondo Beach, California, 90277
GSK Investigational Site
Reno, Nevada, 89502
GSK Investigational Site
Riverside, California, 92506
GSK Investigational Site
Rochester, New York, 14642
GSK Investigational Site
Rockville, Maryland, 20852
GSK Investigational Site
Salisbury, North Carolina, 28144
GSK Investigational Site
San Antonio, Texas, 78238
GSK Investigational Site
San Diego, California, 92117
GSK Investigational Site
San Francisco, California, 94109
GSK Investigational Site
Santa Monica, California, 90404
GSK Investigational Site
Scottsdale, Arizona, 85251
GSK Investigational Site
Shreveport, Louisiana, 71101
GSK Investigational Site
St Louis, Missouri, 63117
GSK Investigational Site
St. Petersburg, Florida, 33702
GSK Investigational Site
Tacoma, Washington, 98405
GSK Investigational Site
Tallahassee, Florida, 32308
GSK Investigational Site
Tampa, Florida, 33603
GSK Investigational Site
Tampa, Florida, 33607
GSK Investigational Site
Tampa, Florida, 33612
GSK Investigational Site
Terre Haute, Indiana, 47802
GSK Investigational Site
Tucson, Arizona, 85741
GSK Investigational Site
Weber City, Virginia, 24290
GSK Investigational Site
Wenatchee, Washington, 98801
GSK Investigational Site
Winston-Salem, North Carolina, 27103
GSK Investigational Site
Yakima, Washington, 98902
Canada11 sites
GSK Investigational Site
Brampton, Ontario, L6T 3J1
GSK Investigational Site
Kelowna, British Columbia, V1Y 3G8
GSK Investigational Site
London, Ontario, N5Y 5K7
GSK Investigational Site
Montreal, Quebec, H2K 4L5
GSK Investigational Site
Niagara Falls, Ontario, L2E 6A6
GSK Investigational Site
Québec, Quebec, G1V 4G2
GSK Investigational Site
Saint Romuald, Quebec, G6W 5M6
GSK Investigational Site
Sherbrooke, Quebec, J1H 4J6
GSK Investigational Site
Thornhill, Ontario, L4J 6W6
GSK Investigational Site
Toronto, Ontario, M9W 4L6
GSK Investigational Site
Trois-Rivières, Quebec, G8T 7A1
About this study
Official title: Study PXN110748: An Efficacy and Safety Study of XP13512 Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN)
The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).
Read the detailed description
The primary purpose of study PXN110748 was to evaluate efficacy and safety of 3 fixed doses of GEn in the treatment of PHN.
- Conditions
- Neuralgia, Postherpetic
- Being tested
- GEn 1200mg/day, GEn 2400mg/day, GEn 3600mg/day, Placebo
- Keywords
- Neuropathic Pain, Post-herpetic neuralgia, PHN
- Medical subject headings
- Neuralgia, Postherpetic, Neuralgia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GEn 1200mg/dayDrug
Also called XP13512/GSK1838262, gabapentin enacarbil
gabapentin enacarbil 1200mg/day
GEn 2400mg/dayDrug
Also called XP13512/GSK1838262, gabapentin enacarbil
gabapentin enacarbil 2400mg/day
GEn 3600mg/dayDrug
Also called gabapentin enacarbil, XP13512/GSK1838262
gabapentin enacarbil 3600mg/day
PlaceboDrug
placebo
| Study group | Role | What they receive |
|---|---|---|
| Placebo | Placebo comparator | placebo Receives: Drug: Placebo |
| GEn 1200mg/day | Experimental | gabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks Receives: Drug: GEn 1200mg/day |
| GEn 2400mg/day | Experimental | gabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks Receives: Drug: GEn 2400mg/day |
| GEn 3600mg/day | Experimental | gabapentin enacarbil 3600mg/day, maintenance treatment 14 weeks Receives: Drug: GEn 3600mg/day |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at the End of Maintenance Treatment (EOMT) Using Last Observation Carried Forward (LOCF) Data
Baseline and EOMT values are the calculated means of the daily 24-hour API scores for each participant during the last 7 days prior to randomization (Baseline) and the earliest date of Week 13 visit/Withdrawal visit/last dose of study drug (EOMT). Participants used a hand-held diary to rate their average pain intensity over the preceding 24 hours, using an 11-point PI-Numerical Rating Scale (0=no pain, 10=pain as bad as you can imagine). LOCF was used if less than 4 days of diary data were provided. Change from baseline was calculated as EOMT score minus Baseline score.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Secondary outcomes (18)
Change From Baseline in the Mean Night-time Average Pain Intensity (API) Score at EOMT Using LOCF Data
Night-time is defined as the time between going to bed at night and rising in the morning. Participants recorded night-time API on a daily basis in the morning upon awakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline wss calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in the Mean Current Morning Pain Intensity Score at EOMT Using LOCF Data
Current pain is defined as the participant's assessment of pain intensity "right now." Participants recorded their current morning pain intensity in the morning upon wakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in the Mean Night-time Worst Pain Intensity Score at EOMT Using LOCF Data
Night-time worst pain is defined as the participant's assessment of their worst pain between going to bed at night and rising in the morning. Participants recorded night-time worst pain in the morning upon awakening using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in the Mean Sleep Interference Score at EOMT Using LOCF Data
Participants assessed sleep interference due to pain on a daily basis using the 11-point NRS (0=pain does not interfere with sleep, 10=pain completely interferes with sleep). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in the Mean Day-time Average Pain Intensity(API) Score at EOMT Using LOCF Data
Day-time is defined as the time between rising in the morning and going to bed at night. Participants recorded day-time API on a daily basis in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in the Mean Current Evening Pain Intensity Score at EOMT Using LOCF Data
Current pain is defined as the participant's assessment of pain intensity "right now." Participants recorded their current evening pain intensity in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in the Mean Day-time Worst Pain Intensity Score at EOMT Using LOCF Data
Day-time worst pain is defined as the participant's assessment of their worst pain between rising in the morning and going to bed at night. Participants recorded day-time worst pain in the evening before bedtime using an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in Pain Quality as Assessed by the Neuropathic Pain Scale (NPS) Summary Scores at EOMT Using LOCF Data
The NPS assesses pain qualities and consists of 11-items, 10 assessed on an 11-point NRS (0=no impact to 10=greatest impact); and 1 open-ended question not used in score calculation. 4 summary scores are calculated: NPS 10 (items 1-7, 9-11), NPS 8 (8 pain descriptor items), NPS Non-Allodynic (NA) (8 NA items), and NPS 4 (4 pain quality items); and range from 0 to 100 (0=no impact and 100=greatest impact). The analysis is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in Pain Characteristics and Intensity as Assessed by the Short Form-McGill Pain Questionnaire (SF-MPQ) at EOMT Using LOCF Data
The SF-MPQ, a general pain instrument, assesses the characteristics and intensity of pain and consists of 15-items assessed on a 4-point scale (0=none, 1=mild, 2=moderate, and 3=severe). 3 summary scores are calculated: sensory score (sum of items 1-11, range 0-33), affective score (sum of items 12-15, range 0-12), total score (sum of items 1-15, range 0-45), where lower scores = lower pain/impact. Analysis is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in Dynamic Allodynia at EOMT Using LOCF Data
Dynamic allodynia (pain in response to a standardized light touch stimulus, a foam brush applied with light pressure to the site of maximum pain) was assessed by an 11-point PI-NRS (0=no pain, 10=pain as bad as you can imagine). Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Number of Participants Who Are Responders on the Patient Global Impression of Change (PGIC) Questionnaire at EOMT Using LOCF Data
The PGIC is a single-item questionnaire designed to provide an overall assessment of treatment from the participant's perspective since the start of the study. It is measured on a 7-point scale, where 1=very much improved and 7=very much worse. A participant is considered a responder if they have a response of "very much improved" or "much improved." EOMT response is defined as the score recorded at the Week13/Withdrawal visit.
Measured: EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Number of Participants Achieving Various Levels of Percent Reduction From Baseline in the Mean 24-hour Average Pain Intensity Score at EOMT Using LOCF Data
Baseline and EOMT scores are the calculated means of the 24-hour average pain scores for each participant during the last 7 days prior to randomization and EOMT, respectively. Percent reduction from baseline was calculated as the [(EOMT score minus the baseline score)divided by the baseline score], multiplied by 100. The PI-NRS is an 11-point scale (0=no pain, 10=pain as bad as you can imagine) by which a participant assesses their 24-hour average pain intensity.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Time to Onset of Sustained Improvement in the 24-hour Average Pain Intensity Score
Sustained improvement in the 24-hour average pain intensity score is defined as at least 2 consecutive days on which the 24-hour average pain intensity score is >=2 points less than the mean 24-hour average pain intensity score at baseline. Time to onset is measured from baseline and was calculated as the first day of event minus the last day of baseline and is expressed in days. Baseline score is the calculated mean of the 24-hour average pain score for each participant during the last 7 days prior to randomization.
Measured: Anytime post-baseline until date of last dose of study medication (up to Week 13)
Change From Baseline in the Mean Daily Dose in Milligrams of Rescue Medication at EOMT Using LOCF Data
Mean daily use of rescue medication (milligrams of acetaminophen) was calculated by determining the average number of tablets taken per day of rescue medication (Commerical Tylenol) during treatment and multiplying that by 500 mg. Baseline and EOMT are as defined for the primary endpoint. Change from baseline was calculated as the EOMT score minus the baseline score. An ANCOVA model with baseline value, BMI, grouped center as covariates was used.
Measured: Baseline and EOMT (Week 13 or early withdrawal)
Change From Baseline in Severity of Pain and the Impact of Pain as Assessed by the Brief Pain Inventory (BPI) at EOMT Using LOCF Data
The BPI, a general pain instrument, assesses the severity and interference of pain; and consists of 6 items assessed on an 11-point NRS (0=no impact and 10=greatest impact). 2 summary scores are calculated: BPI Severity Score (average of first 4 items) and BPI Interference Score (average of 7 responses to item 6); where each summary score ranges from 0 to 10 (0=no impact and 10=greatest impact). Analysis of this endpoint is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in Quality of Life as Assessed by the SF-36 at EOMT Using LOCF Data
The SF-36 is a general health-related quality of life instrument consisting of 36 items with various response options (Yes/No, 5- to 6-point Likert scale). Summary scores are calculated for 8 domains and 2 components (physical and mental); where scores range from 0 to 100 (higher scores = better quality of life). Analysis of this endpoint is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in Emotional Functioning as Assessed by the POMS-B at EOMT Using LOCF Data
The POMS-B, an emotional functioning instrument, assesses mood, tension, and other psychological symptoms and consists of 30-items assessed on a 5-point scale (0=not at all to 4=extremely). 6 summary scores are calculated: Tension/Anxiety, Depression/Rejection, Anger/Hostility, Vigor/Activity, Fatigue/Inertia, and Confusion/Bewilderment; and range from 0-20 (higher scores = more negative mood state). Analysis of this endpoint is based on the change from baseline (BL) (EOMT score minus the BL score) using an ANCOVA model with BL value, BMI, grouped center as covariates.
Measured: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Number of Participants Who Are Responders on the Clinician Global Impression of Change (CGIC) Questionnaire at EOMT Using LOCF Data
The CGIC is a single-item questionnaire designed to provide an overall assessment of treatment from the clinician's perspective since the start of the study. It is measured on a 7-point scale, where 1=very much improved and 7=very much worse. A participant is considered a responder if they have a response of "very much improved" or "much improved." EOMT response is defined as the score recorded at the Week13/Withdrawal visit.
Measured: EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Feb 2008 (estimated)
- Study startFeb 2008
- Primary completionJul 2009
- Study completionJul 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Neuralgia, PostherpeticStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 376 participants (actual)
Sponsor and investigators
- Lead sponsor
- XenoPort, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- GSK Clinical Trials, Study director, GlaxoSmithKline
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00619476
- Sponsor's protocol ID
- 110748
- Status last verified
- Jan 2013
- First submitted
- 7 Feb 2008
- Last updated
- 22 Jul 2013
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2013. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study PXN110748: An Efficacy and Safety Study of XP13512 Compared With a Concurrent Placebo Control in Subjects With Neuropathic Pain Associated With Post-herpetic Neuralgia (PHN)
- ClinicalTrials.gov ID
- NCT00619476
- Acronym / sponsor ID
- 110748
- Conditions
- Neuralgia, Postherpetic
- Keywords
- Neuropathic Pain, Post-herpetic neuralgia, PHN
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 376 participants (actual)
- Lead sponsor
- XenoPort, Inc.Industry (pharma, biotech, devices)
- Study start
- Feb 2008
- Primary completion
- Jul 2009 (actual)
- Study completion
- Jul 2009 (actual)
- First posted
- 21 Feb 2008 (estimated)
- Results
- Posted 20 May 2011
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to determine whether gabapentin enacarbil (XP13512/GSK1838262), hereafter referred to as GEn is effective in the treatment of neuropathic pain associated with post-herpetic neuralgia (PHN).
Detailed description
The primary purpose of study PXN110748 was to evaluate efficacy and safety of 3 fixed doses of GEn in the treatment of PHN.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Placebo | Placebo comparator | Drug: Placeboplacebo |
| GEn 1200mg/day | Experimental | Drug: GEn 1200mg/daygabapentin enacarbil 1200mg/day, maintenance treatment 14 weeks |
| GEn 2400mg/day | Experimental | Drug: GEn 2400mg/daygabapentin enacarbil 2400mg/day, maintenance treatment 14 weeks |
| GEn 3600mg/day | Experimental | Drug: GEn 3600mg/daygabapentin enacarbil 3600mg/day, maintenance treatment 14 weeks |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- 18 years or older
- Female subjects are eligible if of non-childbearing potential or not lactating, has a negative pregnancy, and agrees to use one a specified highly effective method for avoiding pregnancy
- Documented medical diagnosis of PHN of with pain present for at least three months from the healing of a herpes zoster rash
- Baseline 24-hour average pain intensity score ≥ 4.0 based on an 11-point PI-NRS
- Provides written informed consent in accordance with all applicable regulatory requirements
Key exclusion criteria (25 listed)
- Other chronic pain conditions not associated with PHN. However, the subject will not be excluded if:
- The pain is located at a different region of the body; and
- The pain intensity is not greater than the pain intensity of the PHN; and
- The subject can assess PHN pain independently of other pain
- Is unable to discontinue prohibited medications or non-drug therapies or procedures throughout the duration of the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| GEn 1200mg/dayAlso: XP13512/GSK1838262, gabapentin enacarbilgabapentin enacarbil 1200mg/day | Drug | GEn 1200mg/day |
| GEn 2400mg/dayAlso: XP13512/GSK1838262, gabapentin enacarbilgabapentin enacarbil 2400mg/day | Drug | GEn 2400mg/day |
| GEn 3600mg/dayAlso: gabapentin enacarbil, XP13512/GSK1838262gabapentin enacarbil 3600mg/day | Drug | GEn 3600mg/day |
| Placeboplacebo | Drug | Placebo |
Primary outcome
Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at the End of Maintenance Treatment (EOMT) Using Last Observation Carried Forward (LOCF) Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Baseline and EOMT values are the calculated means of the daily 24-hour API scores for each participant during the last 7 days prior to randomization (Baseline) and the earliest date of Week 13 visit/Withdrawal visit/last dose of study drug (EOMT). Participants used a hand-held diary to rate their average pain intensity over the preceding 24 hours, using an 11-point PI-Numerical Rating Scale (0=no pain, 10=pain as bad as you can imagine). LOCF was used if less than 4 days of diary data were provided. Change from baseline was calculated as EOMT score minus Baseline score.
18 secondary outcomes
Change From Baseline in the Mean Night-time Average Pain Intensity (API) Score at EOMT Using LOCF Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in the Mean Current Morning Pain Intensity Score at EOMT Using LOCF Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in the Mean Night-time Worst Pain Intensity Score at EOMT Using LOCF Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in the Mean Sleep Interference Score at EOMT Using LOCF Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in the Mean Day-time Average Pain Intensity(API) Score at EOMT Using LOCF Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in the Mean Current Evening Pain Intensity Score at EOMT Using LOCF Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in the Mean Day-time Worst Pain Intensity Score at EOMT Using LOCF Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in Pain Quality as Assessed by the Neuropathic Pain Scale (NPS) Summary Scores at EOMT Using LOCF Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in Pain Characteristics and Intensity as Assessed by the Short Form-McGill Pain Questionnaire (SF-MPQ) at EOMT Using LOCF Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in Dynamic Allodynia at EOMT Using LOCF Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Number of Participants Who Are Responders on the Patient Global Impression of Change (PGIC) Questionnaire at EOMT Using LOCF Data
Time frame: EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Number of Participants Achieving Various Levels of Percent Reduction From Baseline in the Mean 24-hour Average Pain Intensity Score at EOMT Using LOCF Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Time to Onset of Sustained Improvement in the 24-hour Average Pain Intensity Score
Time frame: Anytime post-baseline until date of last dose of study medication (up to Week 13)
Change From Baseline in the Mean Daily Dose in Milligrams of Rescue Medication at EOMT Using LOCF Data
Time frame: Baseline and EOMT (Week 13 or early withdrawal)
Change From Baseline in Severity of Pain and the Impact of Pain as Assessed by the Brief Pain Inventory (BPI) at EOMT Using LOCF Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in Quality of Life as Assessed by the SF-36 at EOMT Using LOCF Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Change From Baseline in Emotional Functioning as Assessed by the POMS-B at EOMT Using LOCF Data
Time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Number of Participants Who Are Responders on the Clinician Global Impression of Change (CGIC) Questionnaire at EOMT Using LOCF Data
Time frame: EOMT (representing the earliest date of Week 13 visit/withdrawal visit)
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2013.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
Related trials for Neuralgia, Postherpetic
Not yet recruitingPhase 1
Simultaneous Engagement of Networks for Alleviating Pain (SENAP)
Neuropathic Pain, Postherpetic Neuralgia
Active, not recruiting
Transcranial Magnetic Stimulation for Chronic Neuropathic Pain
Chronic Neuropathic Pain, Post-Stroke Pain
Active, not recruitingObservational study
Obesity and Obesity-Related Factors and Risk of Herpes Zoster (Shingles) and Postherpetic Neuralgia
Herpes Zoster (HZ)
Recruiting
The Analgesic Efficacy and Safety of Venlafaxine for Prevention of Postherpetic Neuralgia in Patients With Acute Herpes Zoster
Herpes Zoster, Pain
Not yet recruiting
Efficacy and Safety of Intravenous Dexamethasone Palmitate Treatments in Acute and Subacute Herpes Zoster Pain
Herpes Zoster Pain
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
GSK Clinical Trials study director
GlaxoSmithKline
83 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing GEn 1200mg/day, GEn 2400mg/day and GEn 3600mg/day in people with Neuralgia, Postherpetic, run by XenoPort, Inc. at 83 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 25 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 22 Jul 2013. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 83 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 20 May 2011). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change From Baseline in the Mean 24-hour Average Pain Intensity (API) Score at the End of Maintenance Treatment (EOMT) Using Last Observation Carried Forward (LOCF) Data (time frame: Baseline and EOMT (representing the earliest date of Week 13 visit/withdrawal visit)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2013.